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DOI 10.1186/s12916-015-0326-3RESEARCH ARTICLE Open AccessA systematic review of cost-effectiveness analyses
of complex wound interventions reveals optimal
treatments for specific wound types
Andrea C Tricco1,2, Elise Cogo1, Wanrudee Isaranuwatchai1,3, Paul A Khan1, Geetha Sanmugalingham1,
Jesmin Antony1, Jeffrey S Hoch1,3 and Sharon E Straus1,4*Abstract
Background: Complex wounds present a substantial economic burden on healthcare systems, costing billions of
dollars annually in North America alone. The prevalence of complex wounds is a significant patient and societal
healthcare concern and cost-effective wound care management remains unclear. This article summarizes the
cost-effectiveness of interventions for complex wound care through a systematic review of the evidence base.
Methods: We searched multiple databases (MEDLINE, EMBASE, Cochrane Library) for cost-effectiveness studies that
examined adults treated for complex wounds. Two reviewers independently screened the literature, abstracted data
from full-text articles, and assessed methodological quality using the Drummond 10-item methodological quality
tool. Incremental cost-effectiveness ratios were reported, or, if not reported, calculated and converted to United
States Dollars for the year 2013.
Results: Overall, 59 cost-effectiveness analyses were included; 71% (42 out of 59) of the included studies scored 8
or more points on the Drummond 10-item checklist tool. Based on these, 22 interventions were found to be more
effective and less costly (i.e., dominant) compared to the study comparators: 9 for diabetic ulcers, 8 for venous ulcers,
3 for pressure ulcers, 1 for mixed venous and venous/arterial ulcers, and 1 for mixed complex wound types.
Conclusions: Our results can be used by decision-makers in maximizing the deployment of clinically effective
and resource efficient wound care interventions. Our analysis also highlights specific treatments that are not
cost-effective, thereby indicating areas of resource savings.
Please see related article: http://dx.doi.org/10.1186/s12916-015-0288-5
Keywords: Complex wound, Cost-benefit analysis, Cost-effectiveness analysis, Research design, Skin ulcer,
Systematic reviewBackground
Complex wounds are those that do not heal after a
period of 3 months or more [1]. These types of wounds
are a significant burden on the healthcare system and re-
sult in patient and caregiver stress, economic loss, and
decreased quality of life. At least 1% of individuals living
in high economy countries will experience a complex* Correspondence: sharon.straus@utoronto.ca
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unless otherwise stated.wound in their lifetime [2], and over 6.5 million individ-
uals have a complex wound in the United States alone
[3]. Moreover, these types of wounds have a significant
economic impact. For example, $10 billion United States
dollars (USD) per year in North America is spent
managing complex wounds [4], and 4% of the annual
National Health Service expenditure in the United
Kingdom is spent on care for patients with pressure
ulcers [5].
There are three main categories of complex wounds:
i) wounds resulting from chronic disease (e.g., venous
insufficiency, diabetes), ii) pressure ulcers, and iii) non-
healing surgical wounds [6-8]. Treatment is targeted toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing from disease usually involves improving the under-
lying disease; for example, optimizing diabetes control
for patients with diabetes [9]. A clinical assessment
and history of mobility and neurological disability is
often necessary to treat patients with pressure ulcers
[9]. Considerations for managing surgical wound infec-
tions include previous antibiotic treatment and im-
mune response [3].
It is estimated that the global wound care market will
reach over $22 billion USD annually by 2020 [10]. Due
to the burgeoning costs from the management of pa-
tients requiring complex wound care, policymakers are
interested in finding cost-effective treatments. However,
the cost-effectiveness of all interventions available to
treat complex wounds is currently unclear. As such, we
sought to elucidate cost-effective treatment strategies for
complex wounds through a systematic review of cost-
effectiveness analyses.Figure 1 Study flow diagram.Methods
Protocol
The systematic review question was posed by members
of the Toronto Central Local Health Integrated Network.
In collaboration with the Toronto Central Local Health
Integrated Network, our research team prepared a draft
protocol that was revised to incorporate feedback from
systematic review methodologists, policymakers, and cli-
nicians with expertise in wound care (Additional file 1).
Our protocol also included conducting a related project
comprising an overview of systematic reviews for treat-
ing complex wounds, and these results are available in a
separate publication [11].
Information sources and search strategy
On October 26, 2012, an experienced librarian con-
ducted comprehensive literature searches in the fol-
lowing electronic databases from inception onwards:
MEDLINE, EMBASE, and the Cochrane Library. The
Table 1 Summary characteristics of all cost-effectiveness
analyses (CEAs)
Characteristic No. of CEAs
(n = 59)
Percentage of
CEAs
Original year of values
1982–1996 15 25.4
1997–2000 19 32.2
2001–2005 10 16.9
2006–2010 15 25.4
Year of publication
1988–1996 7 11.9
1997–2001 21 35.6
2002–2006 12 20.3
2007–2012 19 32.2
Country of conduct
Europe (17 from the UK) 34 57.6
North America (16 from USA) 19 32.2
Asia 3 5.1
Australia and New Zealand 3 5.1
Perspective
Public payer 17 28.8
Society 8 13.6
Provider 6 10.2
Health care system 1 1.7
Not reported 27 45.8
Efficacy study design
RCT 44 74.6
Observational 9 15.3
Systematic review of RCT 4 6.8
Systematic reviewa 1 1.7
Pseudo-RCT 1 1.7
Sample sizeb
10–30 4 6.8
31–50 11 18.6
51–100 12 20.3
101–150 5 8.5
151–200 3 5.1
201–400 16 27.1
>400 8 13.6
Patient agec (years)
50–59 5 8.5
60–69 20 33.9
70–79 18 30.5
80–89 8 13.6
Not reported 8 13.6
Table 1 Summary characteristics of all cost-effectiveness
analyses (CEAs) (Continued)
Timeframe
≤12 weeks 28 47.5
13–24 weeks 9 15.3
>24 weeks 22 37.3
Funding sourced
Private 23 39.0
Public 10 16.9
Mixed 6 10.2
Not reported 20 33.9
Type of wound
Venous ulcers 24 40.7
Diabetic ulcers 16 27.1
Pressure ulcers 14 23.7
Mixed wounds 3 5.1
Mixed venous and venous/arterial
ulcers
2 3.4
Unit of effectiveness
Additional wound healed 26 44.1
QALY gained 10 16.9
Ulcer-free time (day/week/month)
gained
9 15.3
Percentage additional reduction of
ulcer (area/volume/volume per week)
8 13.6
Increase in healing rate 2 3.4
Reduction in DESIGN score 1 1.7
Patient-year gained 1 1.7
Hospital-free day gained 1 1.7
Foot-related hospitalization avoided 1 1.7
Interventionse
Dressings 17 24.3
Bandage 12 17.1
Biologics 8 11.4
Topical Tx 8 11.4
Wound care programs 7 10.0
Devices 5 7.1
Skin replacement Tx 4 5.7
Oral Tx 3 4.3
Support surfaces 2 2.9
Stockings 1 1.4
Surgery 1 1.4
Wound cleansing 1 1.4
Unspecified 1 1.4
Comparatorse
Dressings 17 24.3
Bandage 8 11.4
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Table 1 Summary characteristics of all cost-effectiveness
analyses (CEAs) (Continued)
No Tx 6 8.6
Biologics 4 5.7
Stockings 2 2.9
Support surfaces 2 2.9
Topical Tx 2 2.9
Wound care programs 2 2.9
Devices 1 1.4
Surgery 1 1.4
Usual care/Unspecified 25 35.7
QALY, Quality-adjusted life-year; RCT, Randomized clinical trial;
Tx, Therapy/treatment.
aNot specified if the included studies were RCTs.
bFor studies based on a review, this refers to the total sample size of the
combined studies that the data were estimated from.
cAge here refers to mean age or the age used in the model.
dMixed here indicates both private and public funding.
eNumbers do not add up to 59 as some studies contributed data to more than
one category.
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economic studies. The Peer Review of Electronic
Search Strategies (PRESS) checklist [12] was used by
another expert librarian to peer review the literature
search. The search was revised, as necessary, and the
final MEDLINE search is presented in Additional file
2. Full literature searches for the other databases are
available upon request. The reference lists of the in-
cluded studies were searched to identify additional
relevant studies.
Eligibility criteria
Inclusion criteria were defined using the ‘Patients, inter-
ventions, comparators, outcomes, study designs, time-
frame’ (PICOST) framework [13], as follows:
Patients
Adults aged 18 years and older experiencing complex
wounds. Complex wounds included those due to chronic
disease (such as diabetic foot ulcers or venous leg ul-
cers), pressure ulcers (such as decubitus ulcers or bed
sores), and non-healing surgical wounds.
Interventions
All complex wound care interventions were included, as
identified from our overview of systematic reviews [11]
and outlined in Additional file 3.
Comparators
All comparators were eligible for inclusion, including
any of the eligible interventions in comparison with
each other or versus no treatment or placebo or
usual care.Outcomes
Cost-effectiveness (i.e., both incremental cost and incre-
mental effectiveness) was included, where effectiveness
was measured by at least one of the following outcomes:
quality-adjusted life-years (QALYs), wounds healed,
ulcer-free/healing time, wound size reduction/improve-
ment, or hospitalizations (number/length of stay).
Study designs
Economic evaluations were included in which the incre-
mental cost-effectiveness ratios (ICERs) were reported
or could be derived.
Timeframe
We did not limit inclusion to year of publication.
Other limitations
We limited cost-effectiveness analyses to those based on
a study with a control group, and where the data were
from direct comparisons (versus a review using indirect
data). Both published and unpublished studies were eli-
gible for inclusion. Although we focused inclusion on
those studies written in English, we contacted the
authors of potentially relevant non-English studies to
obtain the English translation.
Screening process for study selection
The team pilot-tested the pre-defined eligibility criteria
using a random sample of 50 included titles and ab-
stracts. After 90% agreement was reached, each title and
abstract was screened by two team members, independ-
ently, using our Synthesi.SR tool [14]. Discrepancies
were resolved by discussion or the involvement of a
third reviewer. The same process was followed for
screening full-text articles that were identified as being
potentially relevant after screening their titles and
abstracts.
Data abstraction and data collection process
The team pilot-tested data abstraction forms using a
random sample of five included cost-effectiveness ana-
lyses. Subsequently, two investigators independently read
each article and abstracted relevant data. Differences in
abstraction were resolved by discussion or the involve-
ment of a third reviewer. Data items included study
characteristics (e.g., type of economic evaluation, time
horizon, treatment interventions examined, study com-
parators), patient characteristics (e.g., clinical population,
wound type), and cost-effectiveness results (e.g., ICERs,
cost per QALY, cost per wound healed). The perspective
of the economic evaluation was categorized as: patient,
public payer, provider, healthcare system, or society [15].
Cost-effectiveness studies can have four possible over-
all results, which are often represented graphically in
Table 2 Characteristics of each cost-effectiveness analysis (CEA) for venous ulcers (n = 24)
CEA (Original year of values) Country
(Original currency)
Perspective Efficacy study
design
Sample
size
Population Timeframe Funding sourcea
Augustin 1999 (1989) [22] Germany (DM) Not reported RCT 25 Mean 61 yrs; venous
insufficiency
24 wks Not reported
DePalma 1999 (1998) [23] USA (US$) Not reported RCT 38 Mean 61 yrs; venous
insufficiency
max. 12 wks Private
Glinski 1999 (1998) [24] Poland (PLN) Public payer RCT 140 Mean 65 yrs; venous
insufficiency
24 wks Not reported
Gordon 2006 (2005) [25] Australia (AU$) Society RCT 56 Most >71 yrs; venous
insufficiency
24 wks Not reported
Guest 2012 (2010) [26] UK (£) Public payer Observational 510 Mean 80 yrs; venous
insufficiency
24 wks Private
Iglesias 2006 (2004) [27] UK (£) Public payer SR of RCTs 434 66 yrs; venous
insufficiency
52 wks Public
Iglesias 2004 (2001) [28] UK (£) Public payer RCT 387 Mean 71 yrs; venous
insufficiency
52 wks Public
Jull 2008 (2005) [29] New Zealand (NZ$) Public payer RCT 368 Mean 68 yrs; venous
insufficiency
12 wks Mixed
Junger 2008 (2007) [30] Germany (DM) Not reported RCT 39 Mean 67 yrs; venous
insufficiency
17 wks Private
Kerstein 2000 (1995) [31] USA (US$) Not reported Observational 81 Mean 65 yrs; venous
insufficiency
3 yrs Not reported
Kikta 1988 (1987) [32] USA (US$) Not reported RCT 87 Venous insufficiency;
(ages NR)
24 wks Not reported
Michaels 2009 (2007) [33] UK(£) Public payer RCT 213 Mean 71 yrs; venous
insufficiency
12 wks Public
Morrell 1998 (1995) [34] UK (£) Public payer RCT 233 Mean 74 yrs; venous
insufficiency
52 wks Public
O’Brien 2003 (2000) [35] Ireland (€) Public payer RCT 200 Mean 72 yrs; venous
insufficiency
12 wks Private
Oien 2001 (1997) [36] Sweden (£) Not reported Observational 68 Mean 76 yrs; venous
insufficiency
12 wks Not reported
Sibbald 2001 (1997) [37] Canada (CAN$) Society RCT 293 Elderly; venous
insufficiency
13 wks Private
Taylor 1998 (1987) [38] UK (£) Not reported RCT 36 Mean 75 yrs; venous
insufficiency
12 wks Private
Ukat 2003 (2002) [39] Germany (€) Not reported RCT 89 Mean 69 yrs; venous
insufficiency
12 wks Private
Watson 2011 (2007) [40] UK (£) Public payer RCT 337 Mean 69 yrs; venous
insufficiency
52 wks Public
Pham 2012 (2009) [41] Canada (CAN$) Society RCT 424 Mean 65 yrs; venous
insufficiency; most
fully mobile
max. 52 wks Public
Schonfeld 2000 (1996) [42] USA(US$) Public payer RCT 240 Mean 60 yrs; venous
insufficiency
52 wks Private
Simon 1996 (1993) [43] UK (£) Not reported Observational 901 Venous insufficiency;
(ages not reported)
13 wks Mixed
Carr 1999 (1998) [44] UK (£) Public payer RCT 233 Mean 73 yrs; venous
insufficiency
52 wks Private
Guest 2009 (2007) [45] UK (£) Public payer RCT 83 Mean 71 yrs; venous
insufficiency
52 wks Private
RCT, Randomized clinical trial; SR, Systematic review; wks, Weeks; yrs, Years.
aMixed here indicates both private and public funding.
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Table 3 Characteristics of each cost-effectiveness analysis (CEA) for venous and venous/arterial ulcers (n = 2)
CEA (Original year of values) Country
(Original currency)
Perspective Efficacy study
design
Sample
size
Population Timeframe Funding source
Dumville 2009 (2006) [46] UK (£) Public payer RCT 267 Mean 74 yrs; venous
insufficiency
52 wks Not reported
Ohlsson 1994 (1993) [47] Sweden (SEK) Not reported RCT 30 Median 76 yrs; venous
insufficiency; most female
6 wks Not reported
RCT, Randomized clinical trial; WKS, Weeks; Yrs, Years.
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bilities for the intervention versus a comparator are:
1) more effective and less costly, which we noted as
‘dominant’; 2) more effective and more costly; 3) less ef-
fective and less costly; and 4) less effective and more
costly, which we noted as ‘dominated’. The first pos-
sibility is considered to be cost-effective; whereas
possibility 4 is not cost-effective. Situations 2 and 3
requires judgment by the decision-maker to interpret
[17], and in such cases, the decision is often dependent on
the decision-maker’s willingness to pay. For interventions
that were found to be more effective yet more costly (i.e.,
situation 2) or less effective and less costly (situation 3),
ICERs were reported or derived from both the differencesTable 4 Characteristics of each cost-effectiveness analysis (CE
CEA (Original year of values) Country
(Original currency)
Perspective Efficacy s
design
Abidia 2003 (2000) [48] UK (£) Not reported RCT
Apelqvist 1996 (1993) [49] Sweden (SEK) Society RCT
Edmonds 1999 (1996) [50] UK (£) Provider RCT
Guo 2003 (2001) [51] USA (US$) Society SRb
Habacher 2007 (2001) [52] Austria (€) Society Observati
Horswell 2003 (1999) [53] USA (US$) Not reported Observati
Jansen 2009 (2006) [54] UK (£) Public payer RCT
Jeffcoate 2009 (2007) [55] UK (£) Public payer RCT
McKinnon 1997 (1994) [56] USA (US$) Provider RCT
Persson 2000 (1999) [57] Sweden (US$) Not reported SR of RCT
Piaggesi 2007 (2006) [58] Italy (€) Not reported RCT
Redekop 2003 (1999) [59] The Nether-lands (€) Society RCT
Allenet 2000 (1998) [60] France (FF) Society RCT
Ghatnekar 2002 (2000) [61] France (€) Not reported RCT
Ghatnekar 2001 (1999) [62] UK(US$) Public payer SR of RCT
Hailey 2007 (2004) [63] Canada (CAN$) Public payer SR of RCT
RCT, Randomized clinical trial; SR, Systematic review; wks, Weeks; yrs, Years.
aMixed here indicates both private and public funding.
bNot specified if the included studies were RCTs or not (but states they were prospin cost (i.e., incremental cost) and effectiveness (i.e., incre-
mental effectiveness) between the study’s intervention and
comparator groups using the formula:
(Cost of the intervention – Cost of the comparator) ÷
(Effectiveness of the intervention – Effectiveness of the
comparator)
To assess key variables influencing the cost-
effectiveness results, sensitivity analyses, level of uncer-
tainty in the cost and benefit estimates, and incremental
variabilities (i.e., the variability of the incremental cost
and the variability of the incremental effectiveness), were
reported.
Authors of the included cost-effectiveness analyses were
contacted for data verification, as necessary. Further,A) for diabetic ulcers (n = 16)
tudy Sample
size
Population Timeframe Funding
sourcea
18 Mean 71 yrs; diabetes 52 wks Not reported
41 Included >40 yrs; diabetes 12 wks Mixed
40 Mean 66 yrs; diabetes;
foot infections
2 wks Private
126 60 yrs; diabetes 12 yrs Not reported
onal 119 Mean 65 yrs; diabetes 15 yrs Not reported
onal 214 Mean 54 yrs; diabetes;
mostly African-Americans
52 wks Not reported
402 Mean 58 yrs; diabetes approx. 4 wks Private
317 Mean 60 yrs; diabetes 24 wks Public
90 Mean 60 yrs; diabetes;
limb-threatening foot
infections
3 wks Private
s 500 Median 60 yrs; diabetes 52 wks Private
40 Mean 60 yrs; diabetes 12 wks Private
208 Elderly; diabetes 52 wks Private
235 Diabetes; (ages not
reported)
52 wks Not reported
157 Diabetes; (ages not
reported)
52 wks Private
s 449 Diabetes; (ages not
reported)
52 wks Private
s 305 65 yrs; diabetes 12 yrs Public
ective controlled clinical studies).
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were sorted into the major publication (e.g., most re-
cent paper or largest sample size) and companion re-
port. Our results focus on the major publications
and the companion reports were used to provide
supplementary material.
Methodological quality appraisal
The methodological quality of the cost-effectiveness
analyses was appraised using a 10-item tool developed
by Drummond et al. (Additional file 4) [18]. The items
on this tool include the appraisal of question defin-
ition, description of competing alternatives, effective-
ness of the intervention, consideration of all relevant
costs, measurement of costs, valuation of costs and
consequences, cost adjustment/discounting, incremen-
tal analysis, uncertainty/sensitivity analysis, and discus-
sion of study results. The Drummond score can range
from 0 to 10. Each included cost-effectiveness analysis
was appraised by two team members and conflicts
were resolved by discussion or the involvement of a
third reviewer.
Synthesis
Since the purpose of this systematic review was to
summarize the cost-effectiveness of interventions for
complex wound care, the results are reported descrip-
tively. The costing data from all studies were convertedTable 5 Characteristics of each cost-effectiveness analysis (CE
CEA (Original year of values) Country
(Original currency)
Perspective Efficacy
design
Branom 2001 (2000) [64] USA (US$) Not reported RCT
Burgos 2000 (1998) [65] Spain (Pta) Not reported RCT
Chang 1998 (1997) [66] Malaysia (RM) Not reported RCT
Chuangsu-wanich 2011
(2010) [67]
Thailand (US$) Not reported RCT
Ferrell 1995 (1992) [68] USA (US$) Provider RCT
Foglia 2012 (2010) [69] Italy (€) Provider Observa
Graumlich 2003 (2001) [70] USA (US$) Not reported RCT
Muller 2001 (1998) [71] The Netherlands (NLG) Provider RCT
Narayanan 2005 (2004) [72] USA (US$) Not reported Observa
Payne 2009 (2007) [73] USA (US$) Provider RCT
Robson 2000 (1999) [74] USA (US$) Not reported RCT
Sanada 2010 (2007) [75] Japan (Yen) Not reported Observa
Xakellis 1992 (1990) [76] USA (US$) Not reported RCT
Seberrn 1986 (1985) [77] USA (US$) Not reported RCT
RCT, Randomized clinical trial; SR, Systematic review; wks, Weeks; yrs, Years.
aMixed here indicates both private and public funding.to 2013 USD to increase the comparability of the eco-
nomic results across cost-effectiveness studies. This
process entailed first converting the currencies into USD
using purchasing power parities for the particular year
of the data [19,20], and then adjusting these for inflation
to the year 2013 (rounded to the nearest dollar) using
the consumer price index for medical care in the United
States [21].
Results
Literature search and screening
The literature search identified 422 potentially relevant
full-text articles after screening 6,200 titles and abstracts
(Figure 1). There were 59 included cost-effectiveness
analyses that fulfilled our eligibility criteria and were in-
cluded [22-80], plus an additional three companion re-
ports [81-83].
Study and patient characteristics
The cost-effectiveness analyses evaluated interventions
to treat venous ulcers (41%), diabetic ulcers (27%), and
pressure ulcers (24%) (Table 1). The studies were pub-
lished between 1988 and 2012. Most of the papers were
conducted in the United Kingdom (29%) and United
States (27%). Almost half (49%) reported private or
mixed (private and public) funding sources of the stud-
ies, while one-third (34%) did not report a source of
funding.A) for pressure ulcers (n = 14)
study Sample
size
Population Timeframe Funding
sourcea
20 Mean 72 yrs; bedridden max. 8 wks Not reported
37 Mean 80 yrs 12 wks Private
34 Mean 58 yrs max. 8 wks Private
45 Mean 66 yrs 8 wks Not reported
84 Mean 81 yrs; mostly
Caucasians; most fecal
incontinence
52 wks Mixed
tional 362 Most >80 yrs 4.3 wks Not reported
65 Mean 83 yrs 8 wks Public
24 Mean 73 yrs; all females 12 wks Private
tional 976 Most ≥80 yrs; mostly
Caucasians
approx. 22 wks
36 Mean 73 yrs 4 wks Private
61 Mean 50 yrs; mostly
Caucasians
5 wks Mixed
tional 105 Mean 75 yrs 3 wks Not reported
39 Mean 80 yrs 1.4 wks Mixed
77 Mean 74 yrs 8 wks Not reported
Table 6 Characteristics of each cost-effectiveness analysis (CEA) for mixed wound types (n = 3)
CEA (Original year of values) Country
(Original currency)
Perspective Efficacy study
design
Sample
size
Population Timeframe Funding source
Bale 1998 (1994) [78] UK (£) Not reported RCT 100 Mean 76 yrs max. 8 wks Private
Terry 2009 (2008) [79] USA (US$) Not reported RCT 160 Mean 58 yrs 6 wks Public
Vu 2007 (2000) [80] Australia (AU$) Health care system Pseudo-RCT 342 Mean 83 yrs 20 wks Public
RCT, Randomized clinical trial; wks, Weeks; Yrs, Year.
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(single) randomized clinical trial (75%), only a few based
effectiveness on a systematic review (9%) and 15% were
based on observational studies (Tables 2, 3, 4, 5 and 6).
Almost half (46%) of the economic studies included a
sample size of 10 to 100 patients and the rest had a sam-
ple of >100 patients. In addition, 48% were conducted in
a timeframe of 12 weeks or less, while the other studies
had a duration of >12 weeks follow-up. Across the 59
economic studies, 9 different units of effectiveness were
used, with the most common ones being healed wound
(44%) and QALY (17%). Regarding the perspective of the
cost-effectiveness analysis, almost half (46%) did not re-
port this explicitly and 29% reported using the public
payer perspective.
Methodological quality appraisal
Approximately 71% (42 out of 59) of the cost-
effectiveness analyses had a score of 8 or higher out of a
total possible score of 10 (Additional file 5, Figure 2).
Using the Drummond 10-item tool [18], the key meth-
odological shortcoming across the cost-effectiveness ana-
lyses was that only 51% (30 out of 59) had established the100%
100%
51%
97%
97%
100%
17%
80%
85%
80%
2%
0% 10% 20% 30% 40% 50%
1
2
3
4
5
6
7
8
9
10
Yes No N
Figure 2 Drummond methodological quality summary results (n = 59
described. 3. Effectiveness established. 4. All important and relevant costs a
6. Valuation credibility. 7. Discounting. 8. Incremental analysis performed. 9‘effectiveness’ of the intervention using data from efficacy
studies (i.e., systematic reviews, randomized clinical trials
or observational studies) that had sufficiently large sample
sizes according to the International Conference on
Harmonisation guidelines for establishing efficacy [84].
Consistent methodological strengths across the cost-
effectiveness analyses included a clear research question,
costs and consequences measured in appropriate physical
units, credibly valued costs and consequences, and dis-
counted costs (when applicable).
Cost-effectiveness results
Due to the large number of cost-effectiveness studies in-
cluded and the numerous results, we have focused on
dominant results in the text. However, all of the cost-
effectiveness results are presented in Tables 7, 8, 9, 10 and
11 and the sensitivity analyses, level of uncertainty, and in-
cremental variabilities are outlined in Additional file 6.
Venous ulcers
Twenty-four cost-effectiveness analyses examined inter-
ventions for venous ulcers (Table 7) [22-45,83]. Sixteen
studies found the interventions were dominant (i.e., more0%
0%
49%
3%
3%
0%
20%
15%
20%
0%
0%
0%
81%
0%
0%
0%
60% 70% 80% 90% 100%
ot Applicable
). Items: 1. Well-defined question. 2. Competing alternatives well
nd consequences identified. 5. Measurement accurately performed.
. Allowance made for uncertainty. 10. Discussion.
Table 7 Cost-effectiveness analysis (CEA) outcomes for venous ulcers (n = 24)
CEA (Original year of values) Treatment vs. Comparator ICER summary/
estimate [2013 US$]
Unit of effectiveness Incremental cost
[2013 US$]
Incremental
effectiveness
Augustin 1999 (1989) [22] Hydrocolloid dressing vs.
Vaseline gauze dressing
Dominant Ulcer-free week gained −3,362 1.3
DePalma 1999 (1998) [23] Thera-boot vs. Unna’s boot Dominant Ulcer-free week gained −601 1.71
Glinski 1999 (1998) [24] Micronized purified flavonoid
fraction + SC vs. SC alone
Dominanta Additional wound healed −714 0.19
Gordon 2006 (2005) [25] Community leg club vs.
community home nursing
488a Additional wound healed Not reported Not reported
Guest 2012b (2010) [26] NSBF vs. DBC 18a Percent additional
reduction of ulcer area
146 8
Guest 2012b (2010) [26] NSBF vs. no skin protectant 1a Percent additional
reduction of ulcer area
17 22
Guest 2012b (2010) [26] DBC vs. no skin protectant Dominanta Percent additional
reduction of ulcer area
−129 14
Iglesias 2006 (2004) [27] Pentoxifylline plus compression vs.
placebo plus compression
Dominanta QALY gained −213 0.01
Iglesias 2004 (2001) [28] Four-layer bandage vs.
short-stretch bandage
Dominanta QALY gained −566 0.02
Jull 2008 (2005) [29] Manuka honey dressing vs. UC Dominanta,c Additional wound healed −48 0.06
Junger 2008 (2007) [30] Low-frequency pulsed current
(Dermapulse) vs. placebo
More costly &
more effectived
Percent additional
reduction of ulcer area
Not reported Not reported
Kerstein 2000b (1995) [31] Hydrocolloid dressing plus
compression hosiery vs.
Unna’s boot
Dominant Additional wound healed −6,748 0.18
Kerstein 2000b (1995) [31] Unna’s boot vs. saline gauze
plus compression hosiery
More costly &
more effectived
Additional wound healed Not reported Not reported
Kikta 1988 (1987) [32] Unna’s boot vs. hydrocolloid
(DuoDERM)
Dominanta Additional wound healed −209 0.32
Michaels 2009 (2007) [33] Antimicrobial silver-donating
dressings vs. low-adherent
dressings
917,298a QALY gained 183 0.0002
Morrell 1998 (1995) [34] Community leg ulcer clinics
using four-layer compression
bandaging vs. home nursing UC
7a Ulcer-free week gained 44 5.9
O’Brien 2003 (2000) [35] Four-layer bandage vs. UC Dominanta Increase in healing rate −42 0.2
Oien 2001 (1997) [36] Pinch grafting in primary care vs.
pinch grafting in hospital
Cost saving & same
effectiveness
Additional wound healed −14,075 0
Sibbald 2001 (1997) [37] Skin substitute (Apligraf) plus
four-layer bandage vs. four-layer
bandage only
6095a Additional wound healed 457 0.075
Taylor 1998 (1987) [38] Four-layer high-compression
bandaging vs. UC
Dominanta Additional wound healed −659 0.095
Ukat 2003 (2002) [39] Multilayer elastic bandaging
(Profore) vs. short-stretch
bandaging
Dominanta Additional wound healed −1,198 0.08
Watson 2011 (2007) [40] Ultrasound plus SC vs. SC alone Dominateda QALY gained 371 −0.009
Pham 2012 (2009) [41] Four-layer bandaging vs.
short-stretch bandaging
43,918a QALY gained 395 0.009
Schonfeld 2000 (1996) [42] Apligraf (Graftskin) vs. Unna’s Boot Dominanta Ulcer-free month gained −13,883 2.85
Simon 1996 (1993) [43] Community leg ulcer clinic vs.
UC clinic
Dominant Additional wound healed −1,826 0.22
Carr 1999 (1998) [44] Four-layer compression
bandaging (Profore) vs. UC
Dominanta Additional wound healed −1,289 0.13
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Table 7 Cost-effectiveness analysis (CEA) outcomes for venous ulcers (n = 24) (Continued)
Guest 2009 (2007) [45] Amelogenin plus compression
therapy vs. compression
therapy only
Dominanta QALY gained −835 0.054
DBC, Durable barrier cream; ICER, Incremental cost-effectiveness ratio; NSBF, No sting barrier film; QALY, Quality-adjusted life-year; SC, Standard care; UC, Usual
care; US$, United States dollars.
aDenotes the higher quality studies (Drummond score ≥8).
bMultiple comparisons are reported.
cICER was mostly due to an extra 3 patients hospitalized in control group… “probably due to random variation”. If remove these costs, the dominance is reversed
in favor of UC.
dUnable to calculate specific ICER for these 2 studies because the data was not reported for all treatment arms or presented in a figure only but the overall result
(more costly & more effective) was reported.
Tricco et al. BMC Medicine  (2015) 13:90 Page 10 of 16effective and less costly) [22-24,26-29,31,32,35,38,42-45],
and 12 of these were studies with a Drummond score ≥8
[24,26-29,32,35,38,39,42,44,45]. These included Apligraf
(Graftskin) vs. Unna’s Boot [42], Unna’s boot vs. hydrocol-
loid (DuoDERM) [32], micronized purified flavonoid frac-
tion plus usual care vs. usual care alone [24], durable
barrier cream vs. no skin protectant [26], pentoxifylline
plus compression vs. placebo plus compression [27], Ma-
nuka honey dressing vs. usual care [29], amelogenin plus
compression therapy vs. compression therapy only [45],
and four-layer compression bandaging vs. usual care
[35,38,44]. Although four-layer compression bandaging vs.
short-stretch compression bandaging was found to be
dominant in two studies [28,39]], this intervention was
more effective and more costly in another economic evalu-
ation [41].
Dominant interventions from four studies scoring <8
on the Drummond tool [22,23,31,43] included hydrocol-
loid dressing vs. Vaseline gauze dressing [22], hydrocol-
loid dressing plus compression hosiery vs. Unna’s boot
[31], Thera-boot vs. Unna’s boot [23], and community
leg ulcer clinic vs. usual care clinic [43].
Mixed venous and venous/arterial ulcers
Two cost-effectiveness analyses evaluated interventions for
mixed venous and venous/arterial ulcers (Table 8) [46,47].
Only one study found an intervention to be dominant (and
had a Drummond score ≥8); hydrocolloid (DuoDERM)
dressing was dominant compared to saline gauze [47].
Diabetic ulcers
Sixteen cost-effectiveness analyses examined interven-
tions for diabetic ulcers (Table 9) [48-63]. TwelveTable 8 Cost-effectiveness analysis (CEA) outcomes for venou
CEA (Original year of values) Treatment vs. Comparator ICER summary
[2013 US$]
Dumville 2009 (2006) [46] larval therapy vs. hydrogel 17,757a
Ohlsson 1994 (1993) [47] hydrocolloid (DuoDERM)
dressing vs. saline gauze
Dominanta
ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life-year; US$, Uni
aDenotes the higher quality studies (Drummond score ≥8).studies found the interventions were dominant
[48-50,52-54,56,57,59,61-63], and 10 of these were studies
with a Drummond score ≥8 [49,50,52-54,56,57,59,61,62].
These included becaplermin gel (containing recombinant
human platelet-derived growth factor) plus good wound
care (GWC) vs. GWC alone (note: the various GWC
definitions used are outlined in Table 9) [57,62], cadex-
omer iodine ointment vs. usual care [49], filgrastim vs.
placebo [50], intensified treatment vs. usual care [52],
staged management diabetes foot program vs. usual
care [53], ertapenem vs. piperacillin/tazobactam [54],
ampicillin/sulbactam vs. imipenem/cilastatin [56], Apli-
graf (skin substitute) plus GWC vs. GWC alone [59],
and promogran dressing plus GWC vs. GWC alone
[61]. Hyperbaric oxygen therapy plus usual care vs.
usual care alone was found to be dominant in one
study [63], yet was more effective and more costly in
another economic evaluation [51].
Dominant interventions from studies scoring <8 on the
Drummond tool included hyperbaric oxygen therapy vs.
control [48], and hyperbaric oxygen therapy plus standard
care vs. standard care alone [63].
Pressure ulcers
Fourteen cost-effectiveness analyses evaluated pressure
ulcer interventions (Table 10) [64-77]. Ten studies found
the interventions were dominant [64,67,69,71-77], and four
of these were studies with a Drummond score ≥8
[69,71,76,77]. These included moisture vapor permeable
dressing vs. gauze [for grade II pressure ulcers] [77], ad-
vanced dressings vs. simple dressings [69], and hydrocol-
loid (DuoDERM) vs. gauze [76]. Collagenase-containing
ointment (Novuxol) vs. hydrocolloid (DuoDERM) dressings and venous/arterial ulcers (n = 2)
/estimate Unit of effectiveness Incremental cost
[2013 US$]
Incremental
effectiveness
QALY gained 195 0.011
Additional wound healed −588 0.357
ted States dollars.
Table 9 Cost-effectiveness analysis (CEA) outcomes for diabetic ulcers (n = 16)
CEA (Original year of values) Treatment vs. Comparator ICER summary/
estimate [2013 US$]
Unit of effectiveness Incremental cost
[2013 US$]
Incremental
effectiveness
Abidia 2003 (2000) [48] HBOT vs. control Dominant Additional wound healed −7,596 0.625
Apelqvist 1996 (1993) [49] Cadexomer iodine ointment vs.
standard treatment
Dominanta Additional wound healed −119 0.183
Edmonds 1999 (1996) [50] Filgrastim vs. placebo Dominanta,b Hospital-free day gained −7,738 7.5
Guo 2003 (2001) [51] HBOT + SC vs. SC alone 3508a QALY gained 2,137 0.609
Habacher 2007 (2001) [52] Intensified treatment vs. SC Dominanta Patient-year gained −7,625 2.97
Horswell 2003 (1999) [53] Staged management diabetes
foot program vs. SC
Dominanta Foot-related hospitalization
avoided
−7,848 0.41
Jansen 2009 (2006) [54] Ertapenem vs. Piperacillin/
Tazobactam
Dominanta Lifetime QALY gained −822 0.12
Jeffcoate 2009c (2007) [55] Hydrocolloid (Aquacel) vs.
antiseptic (Inadine)
1449a Additional wound healed 14 0.01
Jeffcoate 2009c (2007) [55] Antiseptic (Inadine) vs.
non-adherent dressing
1590a Additional wound healed 80 0.05
McKinnon 1997 (1994) [56] Ampicillin/sulbactam vs.
imipenem/cilastatin
Dominanta Hospitalization day avoided −5,891 3.5
Persson 2000 (1999) [57] Becaplermin plus GWC
(unspecified) vs. GWC alone
Dominanta Ulcer-free month gained −628 0.81
Piaggesi 2007 (2006) [58] Total contact casting vs. Optima
Diab device
8,578 Additional wound healed 858 0.1
Redekop 2003 (1999) [59] Apligraf (skin substitute) +
GWCd vs. GWC alone
Dominanta Ulcer-free month gained −1,223 1.53
Allenet 2000 (1998) [60] Dermagraft (human dermal
replacement) vs. SC
70,961a Additional wound healed 12,652 0.178
Ghatnekar 2002 (2000) [61] Promogran dressing plus
GWCe vs. GWC alone
Dominanta Additional wound healed −294 0.042
Ghatnekar 2001 (1999) [62] Becaplermin gel (containing
recombinant human
platelet-derived growth factor)
plus GWCf vs. GWC alone
Dominanta Ulcer-free month gained −794 0.81
Hailey 2007 (2004) [63] HBOT + SC vs. SC alone Dominant QALY gained −9,337 0.63
GWC, Good wound care; HBOT, Hyperbaric oxygen therapy; ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life-year; SC, Standard care; US$,
United States dollars.
aDenotes the higher quality studies (Drummond score ≥8).
b“Patient selection may have occurred during the in-hospital stay where more control patients experienced a bad vascular condition requiring the more
costly interventions”.
cMultiple comparisons are reported.
dGWC, “the best wound care available and consists mainly of offloading, debridement, and moist dressings”.
eGWC, “sharp debridement (if necessary) and wound cleansing. In the GWC alone arm, the primary dressing was saline-soaked gauze and the secondary gauze
and tape”.
fGWC, “sharp debridement to remove callus, fibrin and necrotic tissue; moist saline dressing changes every 12 hours; systematic control of infection, if present;
glucose control; and offloading of pressure”.
Tricco et al. BMC Medicine  (2015) 13:90 Page 11 of 16was found to be dominant in one study [71], while col-
lagen (Medifil) vs. hydrocolloid (DuoDERM) was more
effective and more costly in another cost-effectiveness
analysis [70].
The following interventions were dominant in six
studies with a Drummond score <8: constant force
technology mattress vs. low-air-loss mattress [64], sil-
ver mesh dressing vs. silver sulfadiazine cream [67],
balsam Peru plus hydrogenated castor oil plus trypsin
ointment vs. balsam Peru plus hydrogenated castor oil
plus trypsin ointment plus other treatment (unspecified)for stage 1 and 2 wounds [72], balsam Peru plus hydroge-
nated castor oil plus trypsin ointment plus other treat-
ment (unspecified) vs. other treatment (unspecified) for
stage 1 wounds [72], balsam Peru plus hydrogenated
castor oil plus trypsin ointment vs. other treatment
(unspecified) for stage 2 wounds [72], polyurethane foam
dressing vs. saline gauze [73], sequential granulocyte-
macrophage/colony-stimulating factor and basic fibro-
blast growth factor vs. basic fibroblast growth factor
alone [74], sequential granulocyte-macrophage/colony-
stimulating factor and basic fibroblast growth factor vs.
Table 10 Cost-effectiveness analysis (CEA) outcomes for pressure ulcers (n = 14)
CEA (Original year of values) Treatment vs. Comparator ICER summary/
estimate [2013 US$]
Unit of effectiveness Incremental cost
[2013 US$]
Incremental
effectiveness
Branom 2001 (2000) [64] Constant Force Technology
mattress vs. low-air-loss mattress
Dominant Percent additional reduction
in wound volume per week
−1,435 0.04
Burgos 2000 (1998) [65] Collagenase ointment vs.
hydrocolloid (Varihesive) dressing
1,278 Percent additional reduction
of ulcer area
20,825 16.3
Chang 1998 (1997) [66] Hydrocolloid (DuoDERM CGF) vs.
saline gauze
3 Percent additional reduction
of ulcer area
121 43
Chuangsu-wanich 2011
(2010) [67]
Silver mesh dressing vs.
silver sulfadiazine cream
Dominant Increase in healing rate −1,695 11.89
Ferrell 1995 (1992) [68] Low-air-loss bed vs. conventional
foam mattress
58a Ulcer-free day gained Not reported Not reported
Foglia 2012 (2010) [69] Advanced dressings vs. simple
dressings
Dominanta Percent additional reduction
of ulcer area
−132 6
Graumlich 2003 (2001) [70] Collagen (Medifil) vs. hydrocolloid
(DuoDERM)
63,147a Additional wound healed 632 0.01
Muller 2001 (1998) [71] Collagenase-containing ointment
(Novuxol) vs. hydrocolloid
(DuoDERM) dressing
Dominanta Additional wound healed −149 0.281
Narayanan 2005b (2004) [72] Initial wound stage 1: BCT
(balsam Peru + hydrogenated
castor oil + trypsin ointment)
only vs. BCT + Others
(BCT plus Other treatments)
Dominant Additional wound healed −5 0.106
Narayanan 2005b (2004) [72] Initial wound stage 1:
BCT + Others vs. Others
Dominant Additional wound healed −10 0.263
Narayanan 2005b (2004) [72] Initial wound stage 2:
BCT only vs. Others
Dominant Additional wound healed −6 0.16
Narayanan 2005b (2004) [72] Initial wound stage 2:
BCT only vs. BCT + Others
Dominant Additional wound healed −7 0.159
Narayanan 2005b (2004) [72] Initial wound stage 2:
BCT + Others vs. Others
226,208 Additional wound healed 226 0.001
Payne 2009 (2007) [73] Polyurethane foam dressing
(Allevyn Thin) vs. saline gauze
Dominant Additional wound healed −564 0.181
Robson 2000b (1999) [74] Sequential GM-CSF and bFGF vs.
bFGF only
Dominant Percent additional reduction
of ulcer volume
1,357 −0.07
Robson 2000b (1999) [74] Sequential GM-CSF and bFGF vs.
GM-CSF only
Dominant Percent additional reduction
of ulcer volume
−848 1
Robson 2000b (1999) [74] Placebo vs. sequential GM-CSF
and bFGF
735 Percent additional reduction
of ulcer volume
2,205 3
Sanada 2010 (2007) [75] New incentive system vs.
non-introduced control
Dominant reduction in DESIGN score −16 4.1
Xakellis 1992 (1990) [76] Hydrocolloid (DuoDERM) vs. gauze Dominanta ulcer-free day gained −25 2
Sebern 1986b (1985) [77] Grade II PrU: MVP vs. gauze Dominanta percent additional reduction
of ulcer area
−1,925 48
Sebern 1986b (1985) [77] Grade III PrU: MVP vs. gauze 9a percent additional reduction
of ulcer area
217 23
BCT, Balsam Peru plus hydrogenated castor oil plus trypsin ointment; bFGF, Basic fibroblast growth factor; GM-CSF, Granulocyte-macrophage/colony-stimulating
factor; ICER, Incremental cost-effectiveness ratio; MVP, Moisture vapor permeable dressing; PrU, Pressure ulcer; QALY, Quality-adjusted life-year; US$, United
States dollars.
aDenotes the higher quality studies (Drummond score ≥8).
bMultiple comparisons are reported.
Tricco et al. BMC Medicine  (2015) 13:90 Page 12 of 16granulocyte-macrophage/colony-stimulating factor alone
[74], and new hospital incentive system vs. non-
introduced control [75].Mixed wound types
Three cost-effectiveness analyses evaluated mixed com-
plex wound types (Table 11) [78-80]. One study with a
Table 11 Cost-effectiveness analysis (CEA) outcomes for mixed wound types (n = 3)
CEA (Original year of values) Treatment vs. Comparator ICER summary/
estimate [2013 US$]
Unit of effectiveness Incremental cost
[2013 US$]
Incremental
effectiveness
Bale 1998 (1994) [78] Hydrocellular (Allevyn) dressing vs.
hydrocolloid (Granuflex) dressing
26 Additional wound
healed
3 0.13
Terry 2009 (2008) [79] Telemedicine plus WCS consults vs.
WCS consults only
Dominateda Additional wound
healed
2,085 −0.249
Vu 2007 (2000) [80] Multidisciplinary wound care
team vs. UC
Dominantb Additional wound
healed
−346 0.092
ICER, Incremental cost-effectiveness ratio; UC, Usual care; US$, United States dollars; WCS, Wound care specialist.
a“Disproportionate distribution, by chance, in group A [telemedicine plus WCS consults] of large non-healing surgical wounds and large, numerous pressure ulcers”.
bDenotes the higher quality study (Drummond score ≥8).
Tricco et al. BMC Medicine  (2015) 13:90 Page 13 of 16Drummond score ≥8 found that a multidisciplinary
wound care team was dominant compared to usual
care [80].
Discussion
We conducted a comprehensive systematic review to
summarize the cost-effectiveness of interventions for
complex wound care including data from 59 cost-
effectiveness analyses. These economic studies examined
numerous interventions and comparators and used
different outcomes to assess effectiveness. In a few
situations, the intervention considered in one cost-
effectiveness analysis comprised the comparator in
another cost-effectiveness analysis. Therefore, cost-
effectiveness results are presented as comparisons of one
treatment option relative to another.
Based on evidence from 42 cost-effectiveness studies
with a Drummond score ≥8, 22 intervention compari-
sons were dominant (Additional file 7). For venous ul-
cers, these were four-layer compression bandaging vs.
usual care, skin replacement vs. Unna’s Boot, Unna’s
boot vs. hydrocolloid, micronized purified flavonoid
fraction plus usual care vs. usual care, durable barrier
cream vs. no skin protectant, pentoxifylline plus com-
pression vs. placebo plus compression, Manuka honey
dressing vs. usual care, and amelogenin plus compres-
sion therapy vs. compression therapy only. For mixed
venous and venous/arterial ulcers, only hydrocolloid
dressing vs. saline gauze was dominant according to high
quality cost-effectiveness analyses. For diabetic ulcers,
cadexomer iodine ointment vs. usual care, filgrastim vs.
placebo, intensified treatment vs. usual care, staged man-
agement diabetes foot program vs. usual care, ertapenem
vs. piperacillin/tazobactam, ampicillin/sulbactam vs. imi-
penem/cilastatin, skin replacement plus GWC vs. GWC
alone, promogran dressing plus GWC vs. GWC alone,
and becaplermin gel (containing recombinant human
platelet-derived growth factor) plus GWC vs. GWC
alone were dominant. For pressure ulcers, moisture
vapor permeable dressing vs. gauze, advanced dressings vs.
simple dressings, and hydrocolloid vs. gauze weredominant. Finally, for mixed wound types, multidisciplin-
ary wound care team was dominant vs. usual care.
Our results highlight a need for a future network
meta-analysis given the numerous interventions and
comparators available. Network meta-analysis is a statis-
tical technique that can be used to combine direct evi-
dence of effectiveness from head-to-head studies and
indirect evidence of the relative benefits of interventions
versus a common comparator (usually placebo). This
powerful statistical approach can also be used to select
the best treatment option available from a ranking of all
treatments. An attractive property of network meta-
analysis is that it allows researchers and health econo-
mists the opportunity to use the ranking analysis to
generate a de novo cost-effectiveness analysis more effi-
ciently. Another potential future study is to conduct a
systematic review of clinical practice guidelines on com-
plex wounds, and compare the interventions recom-
mended in these with those found to be cost-effective in
our review.
The major methodological quality limitation found in
the included cost-effectiveness analyses was that the ma-
jority did not adequately establish the effectiveness of
the wound care intervention using data from systematic
reviews, randomized clinical trials, or observational stud-
ies that had sufficiently large sample sizes. Moreover,
many of the included economic studies did not report
on uncertainty of the cost-effectiveness estimates, incre-
mental variabilities, or sensitivity analyses, thereby fur-
ther limiting the utility of those results. Further, many of
the cost-effectiveness analyses did not assess long-term
cost-effectiveness, and the choice of timeframe for an
economic evaluation might significantly affect the cost-
effectiveness results. Given the chronic nature of many
types of wounds, economic modeling of a longer time
horizon would provide a clearer picture in many circum-
stances. As an example, an intervention might be more
effective yet more costly in the first 2 months of usage
but it might be cost saving over a 1 year or longer time-
frame due to overall fewer additional interventions
required. Furthermore, most of the cost-effectiveness
Tricco et al. BMC Medicine  (2015) 13:90 Page 14 of 16studies did not include information on patient-reported
quality of life, which is a major limitation of this
literature.
The majority of the included economic studies were
from European countries and 16 were from the United
States. When trying to apply the cost-effectiveness re-
sults to a country-specific context, several factors need
to be assessed such as the perspective of the economic
evaluation (e.g., public payer, healthcare provider), the
type of healthcare system (e.g., publicly-funded health-
care), the local practice of medicine, and local costs.
There are a few limitations related to our systematic
review process worth noting. Due to resource con-
straints, we only included studies written in English.
However, we contacted authors of non-English studies
to obtain the English translations. In addition, although
we contacted authors to share their unpublished data,
only published literature was identified for inclusion. Fi-
nally, due to the numerous number of cost-effectiveness
analyses included, we focused reporting on those with
dominant results and a score ≥8 on the Drummond
tool in the main text. We note that this is an arbitrary
cut-off, and there is not an agreed upon method to pro-
vide a summary score on this tool. However, all of our
results for all studies are presented in the tables and
appendices despite dominance and score on the
Drummond tool.Conclusions
We conducted a comprehensive systematic review of
cost-effectiveness studies for interventions to treat adult
patients with complex wounds. Our results can be used
by decision-makers to assist in maximizing the deploy-
ment of clinically effective and resource efficient wound
care interventions. Our analysis also highlights specific
treatments that are not cost-effective, thus indicating
areas for potential improvements in efficiency. A net-
work meta-analysis and de novo cost-effectiveness ana-
lysis will likely bring additional clarity to the field, as
some of the findings were conflicting.Additional files
Additional file 1: Wound care protocol. Outlines the protocol used in
the systematic review.
Additional file 2: MEDLINE search strategy. Lists MEDLINE search terms.
Additional file 3: Classification of wound care interventions. Lists
the wound care interventions in each classification.
Additional file 4: Drummond’s 10-item checklist tool used for cost-
effectiveness analyses quality appraisal. Provides the descriptions of
the 10 items in Drummond’s 10-item checklist tool.
Additional file 5: Cost-effectiveness analysis methodological quality
appraisal results. Lists the quality appraisal results for the 59 included
cost-effectiveness analyses.Additional file 6: Cost-effectiveness analyses sensitivity analysis,
uncertainty of results and incremental variabilities. Outlines the
sensitivity analyses, level of uncertainty, and incremental variabilities for
the cost-effectiveness analyses results.
Additional file 7: Summary of the less costly and more effective
interventions for studies with a Drummond score ≥8. Lists 42 cost-
effectiveness studies with a Drummond score ≥8.
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